What is Zacks Research’s Forecast for CORT Q3 Earnings?

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Analysts at Zacks Research boosted their Q3 2025 earnings estimates for shares of Corcept Therapeutics in a research report issued on Wednesday, January 29th. Zacks Research analyst K. Das now anticipates that the biotechnology company will post earnings per share of $0.42 for the quarter, up from their prior estimate of $0.41. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q4 2025 earnings at $0.47 EPS, FY2025 earnings at $1.52 EPS and Q4 2026 earnings at $0.73 EPS.

Several other research analysts also recently weighed in on CORT. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Corcept Therapeutics in a research report on Thursday, October 31st. StockNews.com lowered Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 25th. Sandler O’Neill reaffirmed a “buy” rating on shares of Corcept Therapeutics in a research note on Friday, October 18th. Finally, Canaccord Genuity Group boosted their price target on Corcept Therapeutics from $78.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, January 30th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $88.25.

Corcept Therapeutics Stock Performance

NASDAQ:CORT opened at $66.91 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70. The stock has a market capitalization of $7.01 billion, a PE ratio of 53.10 and a beta of 0.58. Corcept Therapeutics has a fifty-two week low of $20.84 and a fifty-two week high of $71.29. The company has a fifty day moving average of $56.34 and a two-hundred day moving average of $47.56.

Insiders Place Their Bets

In related news, insider Sean Maduck sold 20,000 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $50.39, for a total transaction of $1,007,800.00. Following the completion of the sale, the insider now directly owns 85,318 shares in the company, valued at approximately $4,299,174.02. This trade represents a 18.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.88, for a total transaction of $131,736.00. The disclosure for this sale can be found here. Insiders have sold 28,011 shares of company stock valued at $1,461,568 in the last ninety days. 20.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Corcept Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. M&G PLC purchased a new position in Corcept Therapeutics in the third quarter worth approximately $11,173,000. Empowered Funds LLC purchased a new position in shares of Corcept Therapeutics during the 3rd quarter worth $1,784,000. Victory Capital Management Inc. increased its position in shares of Corcept Therapeutics by 49.2% during the 3rd quarter. Victory Capital Management Inc. now owns 41,823 shares of the biotechnology company’s stock worth $1,936,000 after purchasing an additional 13,787 shares during the last quarter. State Street Corp increased its position in shares of Corcept Therapeutics by 0.6% during the 3rd quarter. State Street Corp now owns 3,519,263 shares of the biotechnology company’s stock worth $162,871,000 after purchasing an additional 19,893 shares during the last quarter. Finally, Burney Co. raised its holdings in Corcept Therapeutics by 9.1% in the 4th quarter. Burney Co. now owns 473,821 shares of the biotechnology company’s stock valued at $23,876,000 after buying an additional 39,657 shares during the period. Institutional investors and hedge funds own 93.61% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.